Following India Launch, Dr Reddy's Now Rolls Out Migraine Device Nerivio in Spain

Nerivio, developed by the Israeli and US company Theranica, is a wearable, drug-free device that utilizes Remote Electrical Neuromodulation (NER) technology. 

Hyderabad-based Dr Reddy's Laboratories has launched Nerivio, a migraine treatment device, in Spain through its subsidiary Reddy Pharma Iberia. 

Nerivio, developed by the Israeli and US company Theranica, is a wearable, drug-free device that utilizes remote electrical neuromodulation (NER) technology. 

This device, cleared by the USFDA and received CE marking, is designed to relieve acute and preventive migraine.

The launch of Nerivio in Spain is part of a broader strategy involving multiple exclusive agreements between Dr Reddy's European subsidiaries and Theranica. 

Additionally, these agreements cover the marketing and distribution of Nerivio in several European countries.

This includes Germany, Austria, the Czech Republic, Denmark, Finland, France, Italy, Norway, Poland, Slovakia, Sweden, Switzerland, and the United Kingdom. The UK launch is planned for June next year.

Migraine is the sixth most common illness worldwide and the second leading cause of global disability. 

In Spain, more than five million people suffer from migraines, with women constituting 80% of this group. The prevalence of migraines in Spain stands at 12%, rising to 17% among women.

Nerivio targets adults and adolescents aged 12 and older, providing a noninvasive treatment option for migraines with or without aura. 

The device is worn on the upper arm and controlled via a mobile app. It offers 18 treatment sessions of 45 minutes each. For acute migraine treatment, it should be used within 60 minutes of headache onset. 

Moreover, it should be applied every other day as a preventive treatment. Through its NER technology, Nerivio activates conditioned pain modulation (CPM) by stimulating nociceptive nerve receptors in the skin, triggering a natural pain-relief process in the brainstem.

Nerivio’s India Launch

Dr. Reddy's Laboratories launched Nerivio in India in November 2023, introducing an advanced, USFDA-approved, wearable therapy device designed for drug-free migraine management. 

This prescription-based, non-invasive device is intended for acute and prophylactic (preventive) treatment of migraines, with or without aura, for adults and adolescents aged 12 years and above.

The Nerivio app, available for download on the Google Play Store and the Apple App Store, accompanies the device. 

The app enables users to control the intensity levels of the device and includes an interactive migraine diary for symptom logging, response tracking, and insightful analytics.

Additionally, the app features guided imagery, education, and relaxation (GIER) protocol, significantly increasing response rates when used with Nerivio.

Previously, Dr Reddy's Laboratories selected Amazon Web Services (AWS) as its preferred cloud provider to enhance access to affordable and innovative medicines. 

This collaboration involved migrating Dr Reddy's entire SAP platform to AWS, aiming to accelerate the development of healthcare applications and expand their digital platform. 

Additionally, Dr Reddy's and Amazon partnered to create go-to-market models for long-term growth. 

The partnership sought to leverage AWS's expertise in supporting global healthcare customers and its wide range of cloud technologies and international infrastructure.

Founded in 1984, Dr Reddy's is a global pharmaceutical company that offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter (OTC) products.

The pharmaceutical aims to serve over 1.5 billion patients worldwide by 2030, enabling better patient progress tracking for healthcare providers.